

**Additional Table 1** – SNPs showing *moderate* evidence of association ( $p < 1 \times 10^{-5}$ ) with anti-TNF response.

SNP	Chr	Position (bp)	Minor allele	MAF	All patients (n=444)		Patients with moderate/severe disease activity at baseline (n=413)		Gene(s) in region of association
					$\beta$ (95% CI)	P value	$\beta$ (95% CI)	P value	
rs923880	1	33,987,778	C	0.43	-0.25 (-0.36, -0.14)	$8.3 \times 10^{-6}$			CSMD2
rs41005	2	8,111,231	T	0.33	0.27 (0.16, 0.39)	$4.1 \times 10^{-6}$			-
rs13015080*	2	217,384,482	A	0.31	-0.28 (-0.40, -0.16)	$3.4 \times 10^{-6}$	-0.30 (-0.43, -0.18)	$1.1 \times 10^{-6}$	SMARCAL1
rs1498103*	5	19,839,503	A	0.46	0.24 (0.12, 0.35)	$3.3 \times 10^{-5}$	0.26 (0.15, 0.38)	$5.8 \times 10^{-6}$	CDH18
rs78298618	7	35,571,257	T	0.07	-0.48 (-0.69, -0.28)	$4.6 \times 10^{-6}$			HERPUD2
rs1079467	11	7,969,711	C	0.26	0.29 (0.17, 0.41)	$2.1 \times 10^{-6}$			NLRP10
rs16973500	16	71,965,196	T	0.38	0.24 (0.13, 0.34)	$9.1 \times 10^{-6}$			PKD1L3, IST1, ATXN1L

Abbreviations: Chr: chromosome; MAF: Minor allele frequency;  $\beta$ : regression coefficient; 95% CI: 95% confidence interval.

\* In these 2 regions, increased significance was achieved in the patient subset where those with mild disease activity at baseline had been excluded (n=413).